

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20531
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/811,045	03/16/2001	Robert E. Scott	D6386D

CONFIRMATION NO. 7993

FORMALITIES LETTER



OC00000006040174

Dr. Benjamin Adler
Adler & Associates
8011 Candle Lane
Houston, TX 77071

Date Mailed: 05/04/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- An Abstract not to exceed 150 words in length, commencing on a separate sheet (37 CFR 1.72(b)).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at

09811045 051401

patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED SEP 10 2009



5300 #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Scott, Robert E.

§ 87(2)(b)

ART UNIT:

FILED: March 16, 2001

SERIAL NO.: 09/811,045

EXAMINER:

**FOR: cDNA Encoding P2P Proteins and Uses Of
P2P cDNA Derived Antibodies and
Antisense Reagents In Determining
Proliferative Potential of Normal,
Abnormal, and Cancer Cells in Animals
and Humans**

DOCKET:
D6386/D

Assistant Commissioner of Patents
ATTN: Customer Service Center
Washington, D.C. 20231

**RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS AND
CERTIFICATE OF MAILING UNDER 37 CFR 1.8**


Dear Sir:


In response to a Notice to File Corrected Application Papers mailed May 4, 2001 for the above-referenced patent application, Applicants submit herewith Figures 5 and 6 wherein the figures meet the margin requirements under 37 C.F.R. 1.84. Applicants further submit herewith a Sequence Listing, a computer readable form of the Sequence Listing, a Sequence Compliance Statement and a copy of the Formalities Letter. Please debit any fees that are due from Deposit Account No. 07-1185.

I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: Customer Service Center, US Patent and Trademark Office, Washington, DC 20231. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

DATE: June 8, 2001
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
713/270-5391
BADLER1@houston.rr.com


Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Scott

FILED: March 16, 2001

SERIAL NO.: 09/811,045

FOR: cDNA Encoding P2P Proteins And Use Of P2P
cDNA-Derived Antibodies And Antisense
Reagents In Determining The Proliferative
Potential Of Normal, Abnormal And Cancer
Cells In Animals And Humans

§ ART UNIT:

§ EXAMINER:

§ DOCKET: D6386D

The Assistant Commissioner of Patents and Trademarks
BOX NON-FEE AMENDMENT
Washington, DC 20231

**COMPLIANCE OF REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Dear Sir:

Applicant hereby provides a computer readable form of the Sequence Listing on the enclosed 3.5 inch disk and a paper copy thereof for the above-referenced application. The disk is a 1.44 Mb IBM-formatted disk. The file is stored as D6386D/SEQ in text format. I hereby state that the content of the paper copy of the Sequence Listing filed as part of the above-captioned application and the enclosed computer readable copy of the Sequence Listing are the same.

Respectfully submitted,

Date:

June 8, 2001

Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423

ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
(713) 270-5391

09/811,045